Abstract
BACKGROUND: The mainstay of treatment for adverse events to hyaluronic acid filler is the use of hyaluronidase (HYAL); however, the dose and dilution are not standardized. OBJECTIVES: The objective of this study was to examine differential dilutions and concentrations of HYAL, and to compare the effectiveness of ovine and human HYAL. METHODS: Fillers were selected for study based on a variety of rheologic factors. A 0.2-mL dose of product was selected for use based on previous studies. Degradation was assessed by comparing both ovine and recombinant HYAL over a range of concentrations and dilutions. RESULTS: In the 2:1 dilution group, Restylane Lidocaine (Galderma, Lausanne, Switzerland) was degraded by 100 U of ovine HYAL after 50 minutes. No other filler was completely degraded; Restylane Lyft (Galderma) was partially degraded after 1 hour of treatment with 100 U of HYAL. In both the 3:1 and 4:1 dilution groups, Restylane Shaype (Galderma) and Restylane Lyft fillers were most susceptible to degradation, dissolving within 30 minutes with 100 U of recombinant HYAL and within 40 minutes with 100 U of ovine HYAL. Juvéderm and RHA4 fillers were the most resistant, requiring 300 U of HYAL for degradation within 1 hour. Beyond a 3:1 dilution ratio, no further improvement was observed. CONCLUSIONS: This study demonstrates that 300 U of hyaluronidase is sufficient to degrade 0.2 mL of the most resistant hyaluronic acid fillers within 1 hour. Importantly, a minimum dilution of 3:1 should be used to provide adequate fluid for dissolving filler. Ovine HYAL appears to be just as effective as recombinant HYAL in terms of dissolving product.